CORRECTION article

Front. Pharmacol., 26 July 2023

Sec. Experimental Pharmacology and Drug Discovery

Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1247393

Corrigendum: Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis

  • 1. Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China

  • 2. Osteoporosis and Bone Metabolic Diseases Center, Peking University Third Hospital, Beijing, China

  • 3. Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, China

  • 4. Department of Orthopaedics, Peking University Third Hospital, Beijing, China

  • 5. Beijing Key Laboratory of Spinal Disease Research, Beijing, China

  • 6. Department of Tumor Chemotherapy and Radiation Sickness, Peking University Third Hospital, Beijing, China

Article metrics

View details

1,2k

Views

532

Downloads

In the published article, there was an error in the Funding statement. The original statement read: “This work was supported by National Natural Science Foundation of China (No. 81501387, No. 12172011, No. 11872076), Bethune Osteoporosis Foundation Project (G-X-2020-1107-02) and Youth Backbone Incubation Fund of Peking University Third Hospital (BYSYFY2021027).” This statement should be corrected as follows:

Funding

This work was supported by Scientific Research Foundation of Returned Scholars of Peking University Third Hospital (LXHG2018003), National Natural Science Foundation of China (Nos 81501387, 12172011, and 11872076), Bethune Osteoporosis Foundation Project (G-X-2020-1107-02), and Youth Backbone Incubation Fund of Peking University Third Hospital (BYSYFY2021027).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

nitazoxanide, stat3, osteoclastogenesis, Nfatc1, osteoporosis

Citation

Li C-h, Lü Z-r, Zhao Z-d, Wang X-y, Leng H-j, Niu Y and Wang M-p (2023) Corrigendum: Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis. Front. Pharmacol. 14:1247393. doi: 10.3389/fphar.2023.1247393

Received

26 June 2023

Accepted

04 July 2023

Published

26 July 2023

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

14 - 2023

Updates

Copyright

*Correspondence: Hui-jie Leng, ; Yan Niu, ; Mo-pei Wang,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics